Enhanced Survival and Cure of F98 Glioma–Bearing Rats following Intracerebral Delivery of Carboplatin in Combination with Photon Irradiation

Rousseau, Julia; Boudou, Caroline; Barth, Rolf F.; Balosso, Jacques; Estève, François; Elleaume, Hélène

doi:10.1158/1078-0432.ccr-07-1002

Cited by 65 publications

(57 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, MTDs of these drugs administered by CED were evaluated in the F98 glioma bearing Fischer rats through a dose escalation protocol. Initial doses were chosen with reference to the existing literature [13,19]. Signs of lethargy, groom or feeding cessation, were considered as evidence of intolerable toxicity.…”

Section: Maximum Tolerated Dose (Mtd) and Tumor Uptakementioning

confidence: 99%

“…They reported an improvement of median survival time (MeST) or even cure of glioma bearing rats when combined with radiation therapy [12][13][14][15][16][17]. Additionally, a phase I clinical trial showed that it was safe and feasible to deliver carboplatin by CED to treat glioblastoma [18].…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, a phase I clinical trial showed that it was safe and feasible to deliver carboplatin by CED to treat glioblastoma [18]. However, due to the large diversity of the techniques, animal models, and/or drug dosages used in different studies [12,13,19,20], it is unclear if the CED of one particular platinum-based antineoplastic agent is better than the others. Moreover, it is paramount to evaluate the liposomal formulations of platinum drugs and compare their performance to that of free platinum drugs, particularly since it has been reported that liposomal chemotherapy drugs delivered by CED have longer retention times in the tumor area, and can further extend survival [21].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model

et al. 2015

View full text Add to dashboard Cite

The prognosis for patients with glioblastoma remains poor with current treatments. Although platinum based drugs are sometimes offered at relapse, their efficacy in this setting is still disputed. In this study, we use convection-enhanced delivery (CED) to deliver the platinum-based drugs (cisplatin, carboplatin, and Lipoplatin ™ -liposomal formulation of cisplatin) directly into the tumor of F98 glioma-bearing rats that were subsequently treated with γ radiation (15 Gy). CED increased by factors varying between 17 and 111, the concentration of these platinum-based drugs in the brain tumor compared to intra-venous (i.v.) administration, and by 9-to 34-fold, when compared to intra-arterial (i.a.) administration. Furthermore, CED resulted in a better systemic tolerance to platinum drugs compared to their i.a. injection. Among the drugs tested, carboplatin showed the highest maximum tolerated dose (MTD). Treatment with carboplatin resulted in the best median survival time (MeST) (38.5 days), which was further increased by the addition of radiotherapy (54.0 days). Although the DNA-bound platinum adduct were higher at 4 h after CED than 24 h for carboplatin group, combination with radiotherapy led to similar improvement of median survival time. However, less toxicity was observed in animals irradiated 24 h after CEDbased chemotherapy. In conclusion, CED increased the accumulation of platinum drugs in tumor, reduced the toxicity, and resulted in a higher median survival time. The best treatment was obtained in animals treated with carboplatin and irradiated 24 h later.

show abstract

Section: Maximum Tolerated Dose (Mtd) and Tumor Uptakementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[26,27] на крысах с глиомой F98 использовали карбоплатин в соче-тании с облучением фотонами 6 МВ линейного ускорителя и монохроматического синхротрон-ного источника 89 кýВ ESRF. Полученные ре-зультаты показали терапевтическую ýффектив-ность комбинации карбоплатина с облучением фотонами 6 MV или 80 кýВ.…”

Section: фотон-захватная терапияunclassified

Development of binary technologies of radiotherapy of malignant neoplasms: condition and problems

Sheino¹,

Ижевский²,

Липенгольц³

et al. 2017

Bûll. sib. med.

View full text Add to dashboard Cite

ВВЕДЕНИЕКлючевым моментом для повышения тера-певтической ýффективности лучевой терапии является контрастность, которая заключается в максимизации дозы ионизирующего излучения, подведенной к опухоли и минимизации дозы об-лучения, полученной здоровыми тканями и орга-нами. Широко используемые современные мето-ды лучевой терапии основаны на геометрическом нацеливании излучения на опухоль. Такое наце-ливание реализуется за счет коллимации и фо-

show abstract

“…The first one is contrast enhanced Synchrotron Radiation Therapy (SRT) with extracellular agents like Iodine [2,3]. The second one uses some chemotherapy drugs containing platinum [4,5] or iodine compounds [6,7]. Those drugs penetrate the cell and bind to DNA.…”

Section: Introductionmentioning

confidence: 99%

Synchrotron Radiation Therapy from a Medical Physics point of view

Prezado

Adam

Berkvens

et al. 2010

AIP Conference Proceedings

View full text Add to dashboard Cite

On the possibilities of x-ray phase contrast microimaging by coherent high-energy synchrotron radiation Review of Scientific Instruments 66, 5486 (1995) Abstract.Synchrotron radiation (SR) therapy is a promising alternative to treat brain tumors, whose management is limited due to the high morbidity of the surrounding healthy tissues. Several approaches are being explored by using SR at the European Synchrotron Radiation Facility (ESRF), where three techniques are under development: Synchrotron Stereotactic Radiation Therapy (SSRT), Microbeam Radiation Therapy (MRT) and Minibeam Radiation Therapy (MBRT).The sucess of the preclinical studies on SSRT and MRT has paved the way to clinical trials currently in preparation at the ESRF. With this aim, different dosimetric aspects from both theoretical and experimental points of view have been assessed. In particular, the definition of safe irradiation protocols, the beam energy providing the best balance between tumor treatment and healthy tissue sparing in MRT and MBRT, the special dosimetric considerations for small field dosimetry, etc will be described. In addition, for the clinical trials, the definition of appropiate dosimetry protocols for patients according to the well established European Medical Physics recommendations will be discussed. Finally, the state of the art of the MBRT technical developments at the ESRF will be presented. In 2006 A. Dilmanian and collaborators proposed the use of thicker microbeams (0.36-0.68 mm). This new type of radiotherapy is the most recently implemented technique at the ESRF and it has been called MBRT. The main advantage of MBRT with respect to MRT is that it does not require high dose rates. Therefore it can be more easily applied and extended outside synchrotron sources in the future.

show abstract

Enhanced Survival and Cure of F98 Glioma–Bearing Rats following Intracerebral Delivery of Carboplatin in Combination with Photon Irradiation

Cited by 65 publications

References 46 publications

Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model

Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model

Development of binary technologies of radiotherapy of malignant neoplasms: condition and problems

Synchrotron Radiation Therapy from a Medical Physics point of view

Contact Info

Product

Resources

About